Fig 1: GNG4 expression in LCC and RCC. Comparison of GNG4 mRNA expression (A) between normal controls and patients with LCC, (B) between normal controls and patients with RCC, and (C) between patients with LCC and RCC based on raw data from the colon adenocarcinoma dataset in The Cancer Genome Atlas database. Data were analyzed with GraphPad Prism using two-tailed t-tests (unpaired). *P<0.05; **P<0.01. GNG4, guanine nucleotide binding-protein ? subunit 4; LCC, left-sided colon cancer; RCC, right-sided colon cancer.
Fig 2: Differential analysis of GNG4 expression in Chinese patients with COAD. (A) Transcriptional expression levels of GNG4 in normal controls and patients with COAD. The raw data were obtained from the Oncomine database. Data were analyzed with GraphPad Prism using two-tailed t-tests (unpaired). (B) Differential GNG4 mRNA expression between LCC and RCC was determined using reverse transcription-quantitative PCR. (C) Immunohistochemical staining of GNG4 in normal, LCC and RCC tissues in the tissue microarray. (D) Protein expression levels of GNG4 in normal, LCC and RCC tissues, as measured by western blotting. The graph presents the relative protein expression levels of GNG4 in the aforementioned three tissues (one-way ANOVA, followed by Tukeys post hoc test). *P<0.05; **P<0.01. COAD, colon adenocarcinoma; GNG4, guanine nucleotide binding-protein ? subunit 4; LCC, left-sided colon cancer; RCC, right-sided colon cancer.
Fig 3: Association between GNG4 status and overall survival in patients with LCC and RCC. Clinical data of patients with LCC and RCC were separated from among the raw data in the colon adenocarcinoma dataset in The Cancer Genome Atlas database. Subsequently, the patients with LCC and RCC were grouped based on GNG4 status. The association between GNG4 status and (A) LCC or (B) RCC was analyzed using univariate Cox regression analysis. GNG4, guanine nucleotide binding-protein ? subunit 4; LCC, left-sided colon cancer; RCC, right-sided colon cancer.
Fig 4: Association of GNG4 status with disease stage and overall survival in patients with COAD. (A) Different transcriptional expression levels of GNG4 in COAD samples (n=275) and normal controls (n=349). Gene expression data were collected from the GEPIA 2.0 database and analyzed with GraphPad Prism using two-tailed t-tests (unpaired). (B) Patients with COAD were divided into four groups based on disease stage, including stage I, II, III and IV. Subsequently, the association between GNG4 expression and disease stage was analyzed by one-way ANOVA followed by Tukeys post hoc test. (C) Survival analysis was performed using GEPIA 2.0 in patients with COAD with low and high GNG4 expression. *P<0.05; **, ##, @@P<0.01. COAD, colon adenocarcinoma; GEPIA, Gene Expression Profiling Interactive Analysis; GNG4, guanine nucleotide binding-protein ? subunit 4; TPM, transcripts per million.
Fig 5: Association between GNG4 status and overall survival in Chinese patients with LCC and RCC. Clinical data of patients with LCC and RCC were obtained from the product documentation of the tissue microarray. Based on the status of GNG4, patients with LCC or RCC were divided into two groups each. Subsequently, the association between GNG4 status and (A) LCC or (B) RCC was analyzed using univariate Cox regression analysis. GNG4, guanine nucleotide binding-protein ? subunit 4; LCC, left-sided colon cancer; RCC, right-sided colon cancer.
Supplier Page from Abcam for Anti-GNG4 antibody